Trends in Hospitalizations for Celiac Disease in the United States

Eric P. Borrelli^1,

¹University of Rhode Island College of Pharmacy, Kingston, Rhode Island, United States

Cite this paper:
Eric P. Borrelli. Trends in Hospitalizations for Celiac Disease in the United States. International Journal of Celiac Disease. 2017; 5(4):150-154. doi: 10.12691/ijcd-5-4-5

Abstract

Celiac disease is a severe autoimmune disease that results in patients having an intolerance to gluten. Patients that have celiac disease and ingest gluten can have gastrointestinal related adverse effects. There is currently no cure or treatment for celiac disease outside of a diet consisting of strict adherence to a 100% gluten free diet. However, adherence to a strict gluten free diet is difficult and patients may consume food that is cross-contaminated with gluten which can cause adverse effects that can lead to medical treatment or hospitalizations. Currently, there is only limited published data detailing hospitalizations for celiac disease in the United States. This study analyzed trends in hospitalizations for celiac disease in the United States by utilizing the National Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project net (HCUPnet) using the primary diagnosis code 579.0 celiac disease. The study analyzed total discharges, length of stay for hospitalizations from 1995-2014, as well as mean cost per hospitalizations from 2006-2014. Total number of hospital discharges for celiac disease was trending upward from 1995 to 2014 varied from a low of 391 discharges in 1996 to a high of 1405 in 2010. The mean length of stay varied from a high of 8.69 days in 1996 to a low of 4.88 days in 2014. The mean cost per hospitalization varied from a high of $11,510 in 2013 to a low of $9,247 in 2014. Until there is a cure or therapeutic treatments available, celiac disease will continue to cause hospitalizations and contribute to the cost of healthcare in the United States.

Keywords:
celiac disease acute presentation

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, Elitsur Y, Green PH, Guandalini S, Hill ID, Pietzak M, Ventura A, Thorpe M, Kryszak D, Fornaroli F, Wasserman SS, Murray JA, Horvath K. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003 Feb 10; 163(3): 286-92.
[2]	Dubé C, Rostom A, Sy R, Cranney A, Saloojee N, Garritty C, Sampson M, Zhang L, Yazdi F, Mamaladze V, Pan I, Macneil J, Mack D, Patel D, Moher D. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology. 2005 Apr; 128(4 Suppl 1): S57-67
[3]	Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. Am J Gastroenterol. 2012 Oct; 107(10): 1538-44.
[4]	Patel D, Kalkat P, Baisch D, Zipser R. Celiac disease in the elderly. Gerontology. 2005; 51(3): 213-4.
[5]	Rashtak S, Murray JA. Celiac Disease in the Elderly. Gastroenterology clinics of North America. 2009; 38(3): 433-446.
[6]	Murray JA, Van Dyke C, Plevak MF, Dierkhising RA, Zinsmeister AR, Melton LJ. Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol. 2003; 1(1): 19-27.
[7]	Gujral N, Freeman HJ, Thomson AB. Celiac disease: Prevalence, diagnosis, pathogenesis and treatment. World Journal of Gastroenterology: WJG. 2012; 18(42): 6036-6059.
[8]	Green PH, Lebwohl B, Greywoode R. Celiac disease. J Allergy Clin Immunol. 2015May; 135(5): 1099-106.
[9]	Elli L, Branchi F, Tomba C, et al. Diagnosis of gluten related disorders: Celiac disease, wheat allergy and non-celiac gluten sensitivity. World Journal of Gastroenterology: WJG. 2015; 21(23): 7110-7119.
[10]	Esmaeilzadeh A, Ganji A, Goshayeshi L, Ghafarzadegan K, Afzal Aghayee M, MosanenMozafari H, Saadatniya H, Hayatbakhs A, Ghavami Ghanbarabadi V. Adult Celiac Disease: Patients Are Shorter Compared with Their Peers in the General Population. Middle East J Dig Dis. 2016 Oct; 8(4): 303-309.
[11]	Book L, Zone JJ, Neuhausen SL. Prevalence of celiac disease among relatives of sib pairs with celiac disease in U.S. families. Am J Gastroenterol. 2003 Feb; 98(2): 377-81.
[12]	Rahmoune H, Boutrid N, Amrane M, Bioud B. Triggering agents for transient celiac disease. Internat J Celiac Dis. 2017 Aug; 5 (3): 127-128.
[13]	Rubio-Tapia A, Van Dyke CT, Lahr BD, Zinsmeister AR, El-Youssef M, Moore SB, Bowman M, Burgart LJ, Melton LJ, 3rd, Murray JA. Predictors of family risk for celiac disease: a population-based study. Clin Gastroenterol Hepatol. 2008; 6: 983-7.
[14]	Aomari A, Firwana M, Benelbarhdadi I, Ajana FZ. Celiac disease and cancers in Morocco. Internat J Celiac Dis. 2017 Aug; 5 (3): 108-110.
[15]	Sur LM, Floca E, Sur G, Rednic S. Serological and genetic evidence of Celiac Disease in Juvenile arthritis and rheumatoid arthritis. Internat J Celiac Dis. 2016 Aug; 4 (3) 82-83.
[16]	Zwolińska-Wcisło M, Rozpondek P, Galicka-Latała D, Mach T. [Clinical symptoms variety in adults with celiac disease]. PrzeglLek. 2010; 67: 1325-1328.
[17]	Tankova L, Gerova V, Getsov P, Penkov N, Taneva G, Terziev I, Nakov R. The association of Crohn’s Disease, Celiac Disease, and Selective Ig 1a 1deficiency. Internat J Celiac Dis. 2016 Feb; 4 (1) 30-33.
[18]	Ch’ng CL, Jones MK, Kingham JGC. Celiac Disease and Autoimmune Thyroid Disease. Clinical Medicine & Research. 2007; 5(3): 184-192.
[19]	Chou R, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S. Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017 Mar 28; 317(12): 1258-1268.
[20]	Borrelli EP. Inpatient hospital costs for celiac disease in the United States in 2014. Internat J Celiac Dis. 2017 Aug; 5 (3): 111-114.
[21]	Long KH, RubioO-Tapia A, Wagie AE, et al. The economics of celiac disease: a population-based study. Alimentary pharmacology & therapeutics. 2010; 32(2): 261-269.
[22]	Violato M, Gray A, Papanicolas I, Ouellet M. Resource Use and Costs Associated with Coeliac Disease before and after Diagnosis in 3,646 Cases: Results of a UK Primary Care Database Analysis. Singh SR, ed. PLoS ONE. 2012; 7(7): e41308.
[23]	HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2014. Agency for Healthcare Research and Quality, Rockville, MD. http://hcupnet.ahrq.gov/ Accessed September 5, 2017.
[24]	Borrelli EP, Lee EYK. Hospitalization inpatient costs and demographics for amyotrophic lateral sclerosis in the U.S. from 2010-2014. Int J Recent Sci Res. 2017 July; 8 (7) 18203-18206.
[25]	U.S. Bureau of Economic Analysis. National Income and Product Account Tables, Table 1.1.4 Price Indexes for Gross Domestic Product. [September10, 2017]. http: //bea.gov/iTable/iTable.cfm?ReqID=9&step=1.
[26]	Ludvigsson JF, Rubio-Tapia A, van Dyke CT, et al. Increasing incidence of celiac disease in a North American population. The American journal of gastroenterology. 2013; 108(5): 818-824.
[27]	Riddle MS, Murray JA, Porter CK. The Incidence and Risk of Celiac Disease in a Healthy US Adult Population. Am J Gastroenterol. 2012; 107: 1248-1255.
[28]	Welander A, Tjernberg AR, Montgomery SM, et al. Infectious disease and risk of later celiac disease in childhood. Pediatrics. 2010; 125: e530-e536.
[29]	Aggarwal S, Lebwohl B, Green PHR. Screening for celiac disease in average-risk and high-risk populations. Therapeutic Advances in Gastroenterology. 2012; 5(1): 37-47.
[30]	Glance LG, Stone PW, Mukamel DB, Dick AW. Increases in Mortality, Length of Stay, and Cost Associated With Hospital-Acquired Infections in Trauma Patients. Archives of Surgery (Chicago, Ill: 1960). 2011; 146(7): 794-801.
[31]	Puffer RC, Planchard R, Mallory GW, Clarke MJ. Patient-specific factors affecting hospital costs in lumbar spine surgery. J Neurosurg Spine. 2016; 24: 1-6.
[32]	Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay andhospital costs associated with a pharmacodynamic-based clinical pathway forempiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy. 2010 May; 30(5): 453-62.